Meprin A and meprin alpha generate biologically functional IL-1beta from pro-IL-1beta

Christian Herzog1, Randy S Haun, Varsha Kaushal

  • 1Central Arkansas Veterans Healthcare System, 4300 W. 7th Street, 111D, Little Rock, AR 72205, USA.

Insights

Meprin A and meprin alpha generate active interleukin-1beta (IL-1beta) by cleaving its precursor. This process is crucial for inflammation and tissue injury, as shown in a sepsis model.

Area of Science:

  • Biochemistry
  • Immunology
  • Molecular Biology

Background:

  • Interleukin-1beta (IL-1beta) is a key inflammatory cytokine.
  • Its precursor, pro-IL-1beta, requires specific cleavage for biological activity.
  • Meprin metalloendopeptidases are implicated in various biological processes.

Purpose of the Study:

  • To investigate the role of meprin A and meprin alpha in pro-IL-1beta processing.
  • To compare the biological activity of IL-1beta generated by meprins versus other proteases.
  • To assess the in vivo relevance of meprin-mediated IL-1beta production in a sepsis model.

Main Methods:

  • Purification of meprin A and expression of recombinant meprin alpha.
  • Amino-acid sequencing to identify cleavage sites on pro-IL-1beta.
  • Assay of IL-1beta biological activity using helper T-cell proliferation.
  • Induction of sepsis in mice via cecal ligation puncture and administration of meprin inhibitor actinonin.

Main Results:

  • Meprin A and meprin alpha cleave pro-IL-1beta at the His(115)-Asp(116) bond, generating active IL-1beta.
  • IL-1beta produced by meprin A exhibited 3-fold higher biological activity than that from meprin beta or caspase-1.
  • In a mouse sepsis model, the meprin inhibitor actinonin significantly reduced serum IL-1beta levels.

Conclusions:

  • Meprin A and meprin alpha are potent producers of biologically active IL-1beta.
  • These enzymes cleave pro-IL-1beta at a site distinct from, but near, the caspase-1 site.
  • Meprin A and meprin alpha play a significant role in IL-1beta production during inflammation and tissue injury.

Related Concept Videos

IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...